NBSE News and Press, NeuBase Therapeutics Inc. From 08/13/20

Strong Pharmacokinetic and Pharmacodynamic Data Presented in March Validate Platform and Position Company for Scalable Output of Synthetic Precision Genetic Medicines Company Continues to Progress Candidates in Huntington’s Disease (HD) and Myotonic Dystrophy (DM1) PITTSBURG...

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to addres...

In order to manage its operations and advance its strategic goals, NeuBase Therapeutics ( NBSE +0.3% ) appointed industry veteran William Mann, Ph.D., MBA as COO. More news on: NeuBase Therapeutics, Inc., Healthcare stocks news, Read more ...

PITTSBURGH, July 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, today an...

NeuBase Therapeutics ( NBSE -6.9% ) added to Russell 3000 and Russell Microcap Index, effective today. More news on: NeuBase Therapeutics, Inc., Healthcare stocks news, Stocks on the move Read more ...

PITTSBURGH, June 29, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to addres...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn’s Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn’s regulatory 13F Form filed on 05/15/2020. Please visit our Tracking David Einhorn's Greenlig...

NeuBase Therapeutics (NASDAQ: NBSE ): Q2 GAAP EPS of -$0.26 misses by $0.04 . More news on: NeuBase Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

- - - Announced positive preclinical data that validates the key advantages of the proprietary NeuBase peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform - - - Completed a public offering with net proceeds of approximately $33.3 million in April 2020, strengthen...